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Fig. 1. (A) and (B) Serpiginous polycyclic lesions with erythema and double-edged scales are clinically compatible with ichthyosis 
linearis circumflexa (ILC). (C) Erythematous face with Hertoghe sign and brittle quality of hair is also observed. (D) and (E) 
Reduced scaling and erythema for ILC on extremities after topical pimecrolimus application once daily for six months.
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A Case of Netherton Syndrome Responsive to 
1% Topical Pimecrolimus Cream
Netherton syndrome is a rare autosomal recessive disorder 
associated with mutation of the SPINK5 gene. Its typical ma-
nifestations are the triad of ichthyosis, hair shaft abnorma-
lity, and atopic diathesis. We report a case of Netherton 
syndrome and suggest topical pimecrolimus as a well-tolerated 
agent for truncal lesions. 
A 17-year-old male patient presented with skin lesions 
involving the whole body and hair present shortly after his 
birth. On physical examination, there were polycyclic se-
rpiginous patches with peripheral scales on the extremities 
(Fig. 1A, 1B). Erythematous lesions resembling atopic de-
rmatitis were present on the popliteal fossa area; however, 
they were mild and without lichenification. Also, diffuse 
erythema was noted on the face with a positive Hertoghe 
sign and brittle hair (Fig. 1C). Clinically, the lesions with 
geographic, sharply defined erythema on the trunk were 
compatible with ichthyosis linearis circumflexa (ILC). Patho-
logical findings revealed hyperkeratosis, acanthosis, and para-
keratosis along with perivascular cellular infiltration, mostly 
lymphocytic, in the upper dermis (Fig. 2A). Also, a closer 
inspection of the patient’s hair with light microscopy and 
scanning electromicrography yielded findings suspicious for 
trichorrhexis invaginata (Fig. 2B). Complete blood count and 
routine blood chemistry were all within normal limits; however, 
total IgE was elevated (3,449 IU/mL) and allergen-specific 
IgE to Dermatophagoides farinae was strongly positive (class 
6) on ImmunoCAPⓇ. The combination of ichthyosis, hair 
shaft abnormality, and atopic tendency satisfied the 
diagnostic triad of Netherton syndrome. 
For treatment, 1% topical pimecrolimus ointment was applied 
once daily for 6 months. No adverse events occurred, and 
the most prominent changes occurred over the extremities 
with a reduction of scaly hyperkeratotic plaques (Fig. 1D, 1E). 
However, the facial erythema persisted despite the applica-
Fig. 2. (A) Hyperkeratotis, acan-
thosis, and parakeratosis with pe-
rivascular cellular infiltration, mo-
stly lymphocytic, is found in upper
dermis from trunk lesion suspi-
cious for ILC (H&E, ×200). (B) 
Closer inspection of hair with 
scanning electromicrography (SEM)
revealed finding suspicious for tri-
chorrhexis invaginata (SEM, ×600).
tion of pimecrolimus. There was an approximately ＞50% 
reduction of the Netherton Area and Severity Assessment 
score from the initial value. 
There is no set guideline for the treatment of Netherton 
syndrome. Topical steroid, topical pimecrolimus, tacrolimus, 
calcipotriene, 12% ammonium lactate, systemic retinoid, and 
NB-UVB are some of the options available. Among these 
treatments, pimecrolimus has been suggested as an effective 
choice for ILC1. Treatment with pimecrolimus for 18 months 
caused a dramatic reduction in disease severity and pruritus 
score compared with baseline2. Also, despite concerns of de-
creased protease inhibition within the epidermis and defective 
barrier function increasing the risk of transepidermal water 
loss, skin infection, and, most important, systemic absorption 
of topical drugs3, treatment of 99% of the body surface area 
with pimecrolimus did not result in its increased level in 
blood, assuring its relative safety4. 
The atopic dermatitis on flexural sites and ichthyosis on 
the trunk and extremities in our patient showed improvement 
after treatment with pimecrolimus. However, no effect on 
facial erythema was seen. Diffuse erythema on the face is 
commonly noted in Netherton syndrome. Yet, it is still un-
clear whether the major contributory factors for persistent 
erythema are a result of an ineffective barrier, vasculature 
abnormality, or environmental effects. 
We report an educational case reminding of the classical 
triad of Netherton syndrome and showing the effectiveness 
of topical pimecrolimus. Our patient showed comparable 
results to those reported in Western countries; however, we 
additionally suggest the need for future studies aimed at 
uncovering the mechanism of facial erythema refractory to 
treatment. 
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